Relationship of the HTF9C expression in the breast tumor samples and limph nodes metastases
Abstract
The aim of the study was to assess the level of the HTFC9 protein expression in
primary breast cancer (BC) samples and its correlation with regional
metastases.
Material and
methods. The study included 358 cases of primary BC stages
I–III without neoadjuvant chemotherapy with an assessment of clinical,
morphological and immunohistochemical data, including HTF9C protein expression
level.
Results. In 2 study groups (with and without metastatic lymph node involvement),
a statistically significant relationship was found between HTF9C expression and
estrogen receptor expression (p<0.001) and tumor cells proliferation
index (Ki-67) (p<0.001) depending on the status of regional lymph
node (LN) metastases. No statistically significant relationship was found
between HTF9C expression and patients’ age, the tumor node size, multifocality,
histological subtype (WHO, 2019), grade, progesterone receptor status, HER2
status; and status of LN metastases in 2 study groups. HTF9C protein expression
is statistically significantly associated with regional metastases in breast
cancer (p<0.001). The risk of LN metastases is lower in the absence
of HTF9C expression.
Conclusion. HTF9C may act as an independent predictor of regional lymph node
metastasis in breast cancer.
Keywords: breast cancer; HTF9C; regional metastasis; lymph nodes
Funding. The work was carried out within the framework of the State assignment
“Personalization of adjuvant therapy for patients with luminal Her2-negative
subtypes of breast cancer using a preoperative hormone sensitivity test” (state
registration number of R&D 124020600031-3).
Conflict of
interest. The authors declare no conflict of interest.
For citation: Kometova V.V., Mikhaleva L.M., Rodionov V.V., Rodionova M.V.
Relationship of the HTF9C expression in the breast tumor samples and limph nodes metastases.
Clinical and Experimental Surgery. Petrovsky Journal. 2025; 13 (1): 65–71. DOI:
https://doi.org/10.33029/2308-1198-2025-13-1-65-71 (in Russian)
References
- Chang Y.H., Nishimura S., Oishi H., Kelly V.P., Kuno A., Takahashi S. TRMT2A is a novel cell cycle regulator that suppresses cell proliferation. Biochem Biophys Res Commun. 2019; 508 (2): 410-5.
- Whitfield M.L., Sherlock G., Saldanha A.J., Murray J.I., Ball C.A., Alexander K.E., et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell. 2002; 13: 1977-2000.
- Ring B.Z., Seitz R.S., Beck R., Shasteen W.J., Tarr S.M., Cheang M.C., et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24 (19): 3039-47.
- Bartlett J.M., Thomas J., Ross D.T., Seitz R.S., Ring B.Z., Beck R.A., et al. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res. 2010; 12 (4): R47.
- Bartlett J.M., Bloom K.J., Piper T., et al. Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J Clin Oncol. 2012; 30 (36): 4477-84.
- Martei Y., Matro J. Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes. Breast Cancer. 2015; 7: 337-43.
- Hicks D.G., Janarthanan B.R., Vardarajan R., Kulkarni S.A., Khoury T., Dim D., et al. The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence. BMC Cancer. 2010; 22 (10): 108.